Psilocybin Has Better Response Than Placebo in Antidepressant Trials
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- Patients treated with high-dose psilocybin have better responses than those treated with placebo in antidepressant trials, according to a study published online Aug. 21 in The BMJ.
Tien-Wei Hsu, M.D., from E-DA Dachang Hospital in Kaohsiung, Taiwan, and colleagues examined the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms in a systematic review and Bayesian network meta-analysis. The primary outcome was change in depression, which was measured by the 17-item Hamilton Depression Rating Scale.
The researchers found that compared with antidepression trials of escitalopram, placebo response in psychedelic trials was lower (mean difference, −3.90). Most psychedelics were better than placebo in psychedelic trials, but in antidepression trials of escitalopram, only high-dose psilocybin was better than placebo (mean difference, 6.45). When the reference arm changed from placebo response in the psychedelic trials to antidepressant trials, the effect size of high-dose psilocybin decreased from large to small (standardized mean difference, 0.88 to 0.31, respectively). Compared with escitalopram at 10 mg and 20 mg, the relative effect of high-dose psilocybin was larger (4.66 and 4.69, respectively). Of the interventions, none were associated with higher all-cause discontinuation or severe adverse events than the placebo.
"Serotonergic psychedelics, especially high-dose psilocybin, appeared to have the potential to treat depressive symptoms," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Recent Years Saw Increase in Youth With Anxiety, Depression
MONDAY, April 28, 2025 -- From 2016 to 2022, there was an increase in the proportion of youth who experienced anxiety or depression, according to a research letter published...
USPSTF Recommends Counseling to Prevent Perinatal Depression
FRIDAY, April 25, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends counseling for women at increased risk for perinatal depression (PND). This recommendation...
Medical Debt Tied to Higher Likelihood of Forgone Mental Health Care
FRIDAY, April 25, 2025 -- More than one in seven adults reported carrying medical debt in 2023, and of these, one in three forwent mental health care in the subsequent year...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.